Investing in the
Investing in the
Science of Vitality
Science of Vitality
Dark Matter Longevity Fund backs founders turning the biology of aging into medicine.
Dark Matter Longevity Fund invests in companies translating aging biology into therapeutics. We partner with founders whose science has reached human proof-of-concept and whose work can extend healthy lifespan.
Dark Matter Longevity Fund invests in companies translating aging biology into therapeutics. We partner with founders whose science has reached human proof-of-concept and whose work can extend healthy lifespan.
Personalized Medicine
Longevity Therapeutics Gene therapy. Senolytics. NAD+ metabolism.
Cellular reprogramming. AI drug discovery.
Pre-seed to Phase II.
Clinical Validation
CRISPR therapies are FDA-approved. 15+ senolytic compounds are in human trials. Core aging processes are now pharmacologically modifiable. The science is no longer theoretical — it's clinical.
Clinical Validation
CRISPR therapies are FDA-approved. 15+ senolytic compounds are in human trials. Core aging processes are now pharmacologically modifiable. The science is no longer theoretical — it's clinical.
Structural Biology
AlphaFold has mapped 200M+ protein structures. New biomarkers provide continuous measurement of biological age, risk, and response. Drug targets invisible five years ago are now designable.
Structural Biology
AlphaFold has mapped 200M+ protein structures. New biomarkers provide continuous measurement of biological age, risk, and response. Drug targets invisible five years ago are now designable.
Market Formation
The global longevity market is projected to exceed $600B by 2030. The gap between what science can do and what patients can access is where investment returns concentrate.
Market Formation
The global longevity market is projected to exceed $600B by 2030. The gap between what science can do and what patients can access is where investment returns concentrate.
Founder Migration
A path to IND that once cost $10-15M now runs $3-5M. Repeat founders from software are entering longevity biotech. Infrastructure costs have dropped 70% in five years.
Founder Migration
A path to IND that once cost $10-15M now runs $3-5M. Repeat founders from software are entering longevity biotech. Infrastructure costs have dropped 70% in five years.
Clinical Validation
CRISPR therapies are FDA-approved. 15+ senolytic compounds are in human trials. Core aging processes are now pharmacologically modifiable. The science is no longer theoretical — it's clinical.
Market Formation
The global longevity market is projected to exceed $600B by 2030. The gap between what science can do and what patients can access is where investment returns concentrate.
Structural Biology
AlphaFold has mapped 200M+ protein structures. New biomarkers provide continuous measurement of biological age, risk, and response. Drug targets invisible five years ago are now designable.
Founder Migration
A path to IND that once cost $10-15M now runs $3-5M. Repeat founders from software are entering longevity biotech. Infrastructure costs have dropped 70% in five years.
About the Fund
Positioned for the
Positioned for the
Longevity Inflection
Longevity Inflection
Network
Global Deal Flow
350+ Exosphere alumni across 50+ countries. Direct relationships with founders in Silicon Valley, Latin America, and European biotech hubs.
Longevity
Science
Network
Global Deal Flow
350+ Exosphere alumni across 50+ countries. Direct relationships with founders in Silicon Valley, Latin America, and European biotech hubs.
Longevity
Science
Network
Global Deal Flow
350+ Exosphere alumni across 50+ countries. Direct relationships with founders in Silicon Valley, Latin America, and European biotech hubs.
Longevity
Science
Track Record
Deployment History
$70M+ deployed across 50+ companies in 16 countries via Seraph syndicate. Deep domain experience in gene therapy, genomics, and AI drug discovery.
Trust By Design
Rigour
Track Record
Deployment History
$70M+ deployed across 50+ companies in 16 countries via Seraph syndicate. Deep domain experience in gene therapy, genomics, and AI drug discovery.
Consumer
Rigour
Track Record
Deployment History
$70M+ deployed across 50+ companies in 16 countries via Seraph syndicate. Deep domain experience in gene therapy, genomics, and AI drug discovery.
Trust By Design
Rigour
Scale
A Track Record That Speaks
Investing partners whose outcomes are several standard deviations above venture in general — including biotech and health. 100M+ users reached across consumer products.
Discovery
Growth
Consumer Scale
A Track Record That Speaks
Partners with exits to Konami, Trimble, and Activision. Consumer products reaching 100M+ users (League of Legends, The Sims). Experience scaling from early validation to mass adoption.
Discovery
Growth
Scale
A Track Record That Speaks
Investing partners whose outcomes are several standard deviations above venture in general — including biotech and health. 100M+ users reached across consumer products.
Discovery
Growth
Dark Matter Longevity Fund
Meet the Team
Behind the Science
Leadership Investment professionals with operational backgrounds in gene therapy, consumer products, and venture infrastructure.
Dark Matter Longevity Fund
Meet the Team
Behind the Science
Leadership Investment professionals with operational backgrounds in gene therapy, consumer products, and venture infrastructure.
Dark Matter Longevity Fund
Meet the Team
Behind the Science
Leadership Investment professionals with operational backgrounds in gene therapy, consumer products, and venture infrastructure.